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Coadministration of thiazides increases the efficacy of loop diuretics
even in patients with advanced renal failure. It is commonly assumed
that thiazide diuretics are ineffective in patients with advanced renal
failure (GFR < 30 mI/min/1.73 m2). Thiazides act on the nephron seg-
ment distal to the ascending thick loop of Henle, that is, the site of action
of loop diuretics. Blockade of sodium reabsorption in the thiazide-
sensitive segment should therefore obliterate the compensatory increase
in sodium reabsorption seen after administration of loop diuretics and
thus potentiate the natriuretic efficacy of loop diuretics even in advanced
renal failure. In a single-blind, randomized, placebo controlled crossover
study we compared the natriuretic and chloruretic effect of the loop
diuretic, torasemide, given alone or in combination with the thiazide
diuretic, butizid, in 10 patients with advanced renal failure (mean C1,,
13.1 5.9 ml/min/1.73 m2). For two weeks patients adhered to a diet
containing a standardized amount of Na and K. On the 6th and
13th study days, two sham infusions were given to patients in order
to assess basal 24-hour urinary electrolyte excretion. On the 7th and
14th days they were randomly allocated to receive either 50 mg i.v.
torasemide in combination with a sham infusion or torasemide in
combination with 20 mg i.v. butizid. Administration of torasemide alone
significantly (P C 0.01) increased mean cumulative 24-hour excretion of
sodium (from 154 30 to 232 59 mmol/24 hr) and chloride (from 128
21 to 233 84 mmol/24 hr) as compared with baseline. Administration
of torasemide in combination with butizid caused an even more marked
increase of mean cumulative sodium (from 156 33 to 290 76 mmol/24
hr) and chloride excretion (from 128 29 to 309 99 mmol/24 hr). The
mean cumulative sodium and chloride excretion was significantly greater
with coadministration of butizid as compared with torasemide alone (P C
0.01). Despite the high sodium load with the diet three patients had an
antinatriuretie rebound after the action of torasemide had dissipated. The
rebound was abrogated by coadministration of butizid. In conclusion,
thiazide diuretics markedly potentiate the natriuretic and chloruretie
action of loop diuretics even in patients with advanced renal failure: (i) by
amplifying sodium and chloride excretion and, at least in some patients,
(ii) by interfering with the antinatriuretie rebound. Coadministration of
thiazide diuretics with loop diuretics is therefore rational even in advanced
renal failure.
It is commonly assumed that thiazide diuretics are ineffective in
patients with advanced renal failure, that is, in patients with a
glomerular filtration rate below 30 ml!min!1.73 m2 [1—3]. Thia-
aides interfere with sodium and chloride reabsorption in the distal
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tubule [4, 5]. Since under normal circumstances only about 5 to
10% of filtered sodium reach the tubular site of action of
thiazides, natriuresis can increase only by that amount, so that the
increment of sodium excretion rate in the final urine is modest
[1—3]. The fractional excretion of sodium (FENJ, that is, the
proportion of filtered sodium which is excreted in the final urine,
increases even in patients with advanced renal failure after
thiazide administration [6], although the net increase in absolute
sodium excretion remains modest [6—8].
In patients with nephrotic syndrome and in patients with heart
failure addition of thiazides to furosemide markedly increased
natriuresis [9—11]. Sigurd, Olesen and Wennevold [11] argued
that increased tubular sodium rejection induced by a ioop diuretic
stimulates net sodium reabsorption in more distal sites as a result
of increased delivery of sodium. Some authors suggested that
thiazides may abrogate such compensatory stimulation of distal
sodium reabsorption [11, 12]. Mechanisms augmenting the trans-
port capacity of the distal tubule in response to chronically
increased sodium delivery include epithelial cell hypertrophy [13},
increased basolateral Na-K-ATPase activity [14], increased
numbers of thiazide-sensitive NaCI transporters [15], and in-
creased traneellular NaC1 transport capacity [16]. These consid-
erations are particularly pertinent in chronic renal failure, when
endogenous factors inhibit Na reabsorption in more proximal
nephron segments so that a high sodium load is delivered to the
distal tubule [1—3].
When analyzing the effect of a diuretic agent it is important
to measure the sodium and chloride excretion not only during
the phase of diuresis, but also during the phase of compensatory
increase in sodium reabsorption after the action of the diuretic
has waned, the so-called "rebound phase" [3, 12]. While such
rebound has been well documented in individuals with normal
renal function [17—19], it is not clear whether it also occurs in
advanced renal failure. This point is of importance since thiazides
are uniquely suited to interfere with rebound antinatriuresis
because of their long half-life of action. It was the purpose of
the present single-blind, randomized, placebo controlled cross-
over study to compare natriuresis and ehloruresis following
intravenous administration of a loop diuretic (torasemide) in
combination with either a placebo infusion or infusion of a
thiazide diuretic (butizid). The study was performed in 10 patients
with advanced renal failure on controlled intake of sodium
chloride.
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Table 1. Clinical data of patients studied
Pat.
Age
years Sex Renal disease
S.
mg/dl
GFR (C) RPF (CPAH) PTH
pmol/liter
.
Antihypertensive
drugsmI/mm /1.73 m2
H.L. 61 M Wegener's gran. 9.6 7.1 31.7 33 enalapril, nitrendipine
C.S. 54 F AN 7.2 8.6 29.3 49 clonidine
ES. 55 F GNS 8.8 8.8 24.8 24 nitrendipine
H.B. 66 M Renal TBC 8.5 9.1 37.2 30 enalapril, clonidine
J.G. 62 M IgA GN 6.5 11.1 37.3 46 enalapril
R.N. 61 M AN 4.3 11.6 59.9 28 nifedipine
MS. 39 M IgA GN 5.8 11.8 68.5 51 enalapril
R.N. 48 M GNS 4.2 17.6 65.6 7 captopril
K.S. 45 M GNS 3.2 20.2 73.9 5 captopril, clonidine
G.K. 56 M Hypert. renal dis. 3.2 25.0 99.6 19 nifedipine, atenolol,
clonidine, enalapril
Abbreviations are: GN, biopsy confirmed glomerulonephritis; GNS, glomerulonephritis suspected; AN, analgesic nephropathy; Scr, serum creatinine;
GFR, glomerular filtration rate measured with inulin clearance; RPF, renal plasma flow measured with PAH clearance; PTH, parathormone.
Table 2. Mean fractional sodium (FEN) and chloride (FE1) excretion
Collection periods h
1—3 3—6 6—12 12—24
FEN, %
Baseline (5 + S) 6.5 3.5 6.6 2.7 3.4 1.4 5.8 2.8
T + S 18.5 7.6 12.1 4.1 1.6 5.3
Baseline (S + 5) 6.4 4.0 6.5 3.4 3.3 1.3 5.5 2.0
T + B 20.2 5.8 16.1 6.1a 5.6 25b 6.7 3.5
FE1 %
Baseline (5 + 5) 7.1 3.2 7.0 2.9 4.0 2.1 5.7 2.7
T + S 25.3 9.1 17.0 5.8 5.5 2.7 5.8 3.8
Baseline (S + S)
T + B
7.2 3.1
28.5 7.7
7.1 3.4
23.0 94a
3.8 2.3
8.8 3•0b
5.6 2.0
8.5 3.4"
FENCC 9% 33% 37% 26%
FECIC 13% 35% 60% 47%
Abbreviations are: 5, sham infusion; T, torasemide infusion; B, butizid
infusion.
a P < oo5, bP < 0.01, torasemide plus placebo vs. torasemide plus
butizid
FENa and FEE, in the combination period (T + B) as percent above
FENa and FEE, in the monotherapy period (T + S)
Methods
Patients
Ten patients with known advanced renal failure (C1,, < 30
ml/min/1.73 m2) were examined (Table 1) after written informed
consent had been obtained. Routine blood chemistry and urine
analysis were performed at entry into the study. Diuretic medica-
tion was withheld for at least two weeks prior to the start of the
study (wash-out phase). Other antihypertensive agents were not
washed out, but their dosage was kept unchanged throughout the
study (Table 1).
Protocol
The protocol of the present study was approved by the ethics
committee of the University of Heidelberg. A single-blind, pla-
cebo controlled crossover design was used. For two weeks patients
adhered to a diet containing a standardized amount of sodium
and potassium. The diet was prepared as precooked deep frozen
meals with a standardized Na" content of 150 mmol/day and K
content of 50 mmol/day. In three patients, who required in excess
of 120 mg furosemide per day prior to the wash-out phase and
who had striking edema in the wash-out phase, only 100 mmol
Na per day was given. In addition, patients were instructed to
keep the daily fluid intake constant, that is, to drink about 2 liters
of NaHCO3-containing mineral water per day.
On study day 6 and day 13 the patients received two sham
infusions with 50 ml of 5% glucose solution. On study day 7 and
day 14 they were allocated to receive either the loop diuretic
torasemide (50 mg i.v. dissolved in 50 ml of 5% glucose solution)
in combination with a sham infusion or torasemide in combination
with infusion of the thiazide diuretic butizid (20 mg i.v. dissolved
in 50 ml 5% glucose solution). The patients were allocated to the
different treatment sequences using random numbers. The intra-
venous route of drug administration was chosen to avoid potential
interference with intestinal absorption in uremia. The infusions
were given at 8 a.m. over a period of 15 minutes after blood
samples for estimation of plasma creatinine and electrolytes had
been taken. Mean arterial blood pressure (MAP) was measured at
regular intervals before drug administration and thereafter. On
the study days patients were examined in a quite environment in
recumbent position during the first six hours; afterwards, they
were up and about. They collected urine over 24 hours from 8 a.m.
to 11 a.m. (3 hr), from 11 a.m. to 2 p.m. (3 hr), from 2 p.m. to
8 p.m. (6 hr) and from 8 p.m. to 8 a.m. of the next day (12 hr) for
measurement of urinary sodium, chloride, potassium, calcium and
magnesium excretion, urine volume and osmolality. In addition,
urinary excretion of torasemide and its main metabolites was
assessed in all urine specimens on study days 7 and 14. On study
day 6 glomerular filtration rate (GFR) and effective renal plasma
flow (ERPF) were assessed using the inulin (C1,,) and paraami-
nohippurate (CPAH) clearance methods as described elsewhere
[20]. Body weight was assessed on all study days.
Torasemide is a loop diuretic with a relative long half-life of
action, that is, about six hours. The dose of torasemide chosen (50
mg) is equivalent to about 150 to 200 mg of furosemide [21].
Butizid, or isobutyihydrochlorothiazide (also known as buthia-
zide), is a thiazide which is derived directly from hydrochiorothi-
azide by addition of an isobutyl group. The dose of butizid used in
the present study (20 mg) is equivalent to about 30 mg of
hydrochlorothiazide [22]. The standard dose of butizid in hyper-
tensive patients with normal renal function is 10 mg.
Measurements and calculations
Plasma and urine electrolytes were measured with flame pho-
tometry (Eppendorf 5051, Hamburg, Germany), creatinine with
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autoanalyzer (Hitachi 705, Boehringer Mannheim, Germany),
plasma and urine concentrations of magnesium with atomic
adsorption-spectometry (Perkins & Elmer, Uberlingen, Germa-
ny). The concentrations of torasemide and its main metabolites
(Ml, M3, M5) in urine were determined with high pressure liquid
chromatography (HPLC). The detection limit was 50 ng/ml [23],
Inulin was determined enzymatically (Inutest', Levosan GmbH,
Austria) [24], paraaminohippurate (NephrotestR, Biologische Ar-
beitsgemeinschaft GmbH, Germany) after the method of Braton-
Marshall [25]. MAP was measured oscillometrically using an
automatic blood pressure monitoring device (Dinamap', Critikon
Co., USA). The fractional excretions of sodium (FENa) and
chloride (FE1) were calculated as the ratio between urinary Na
(UNa x V) and Cl (U1 x V) excretion rate and filtered Na
(C1 X plasma Nat) and C1 (C1 x plasma C) load.
Statistics
The primary efficacy parameters were the differences in mean
cumulative 24-hour sodium and chloride excretions: (i) after the
sham infusions, and (ii) after administration of torasemide plus
placebo or torasemide plus butizid, respectively. Because of the
relatively small number of patients, data were analyzed using the
non-parametrical Kruskal-Wallis test for multiple comparisons,
which does not depend on normal Gaussian distribution. If this
procedure gave a significant difference, Wilcoxon's test for paired
samples was applied to compare the respective treatments. Our
analysis also permitted us to exclude a sequence effect [26]. Other
parameters were similarly compared with the respective tests. In
addition, for descriptive purposes the time course of FENa and
FE1 after administration of torasemide plus placebo and to-
rasemide plus butizid was analyzed with ANOVA (Table 2).
Fig. 1. Mean 24-hour cumulative sodium (A)
and chloride (B) excretion in patients with
advanced renal failure (n = 10) after sham
infusion (S + 5), infusion of torasemide plus
placebo (T + 5) or in combination with butizid
(T + B). C 0.05, tP C 0.01, sham vs.
drug administration; #P C 0.05, ##P C 0.01,
i_!.!_ L±IJ torasemide plus placebo vs. torasemide plus
I I butizid.
Differences were assumed to be statistically significant at a P level
of 0.05. Data are shown as mean SD.
Results
Urinary sodium and chloride excretion
Figure 1 shows the mean cumulative 24-hour sodium (Fig. 1A)
and chloride (Fig. 1B) excretion in our patients with advanced
renal failure. Administration of torasemide alone significantly
(P c 0.01) increased cumulative 24-hour sodium and chloride
excretion over baseline, that is, during sham infusion on the
preceding day. The mean cumulative 24-hour sodium and chloride
excretion was greater with coadministration of butizid as com-
pared with torasemide alone. In the paired Wilcoxon test the
difference between torasemide plus placebo versus torasemide
plus butizid was highly significant (P < 0.01). Three out of ten
patients received 100 mmol Nat/day instead of 150 mmol Na7
day (for the safety considerations described above); the variance
of mean cumulative sodium (and chloride) excretion was there-
fore relatively large. The variance was considerably reduced if
mean urinary sodium excretion is expressed as percent of daily
intake, It was 114 9% with the first sham infusion and 179
60% with infusion of torasemide plus placebo (that is, in the first
study arm) compared to 115 10% with the second sham infusion
and 223 78% with administration of torasemide plus butizid
(that is, in the second study arm).
The increment in urinary sodium and chloride excretion over
baseline became progressively less with time, but in all collection
periods the increment was greater with combined torasemide plus
butizid administration than with torasemide plus placebo (Fig. 2
A and B). Table 2 clearly illustrates that the increase of mean
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Fig. 2. Mean hourly excretion of sodium (A) and chloride (B) after sham
infusion, infusion of torasemide plus placebo or in combination with butizid.
Symbols are: (0) sham infusion day before infusion of torasemide plus
placebo; (•) sham infusion day before infusion of torasemide plus butizid;
(Li) infusion of torasemide plus placebo; (A) infusion of torasemide plus
butizid.
FENa and FE1 in the combination treatment period (torasemide
plus butizid) rose progressively with time over mean FENa and
FE1 in the mono-treatment period (torasemide plus placebo),
indicating that the superior efficacy of the combination became
more pronounced as time went by.
If antinatriuresis is defined as the decrease of urinary Na
excretion below the baseline excretion of the preceding (sham
infusion) day, three patients could be identified who had a
clearcut rebound phenomenon with torasemide plus placebo. As
shown in Figure 3, in all three patients the rebound was abrogated
by coadministration of butizid.
Other parameters
Table 3 gives mean cumulative 24-hour urine volume as well as
urinary osmolar, potassium, calcium and magnesium excretion
and mean 24-hour endogenous creatinine clearance (Car). There
was no significant difference in mean potassium and magnesium
excretion with torasemide plus placebo versus torasemide plus
butizid when analyzed with the Kruskal-Wallis test. In contrast,
with the combination of diuretics the mean cumulative urinary
calcium excretion was significantly less (P < 0.05) than with
torasemide plus placebo. Mean diuresis (that is, urine volume)
was significantly greater (P < 0.05) with the combination of
diuretics than with torasemide plus placebo, whereas 24 hours Cr
did not change significantly. It remained stable after administra-
tion of torasemide plus placebo (ito 3 hours post-infusion: 15.1
8.9 ml/min/1.73 m2; 3 to 6 hours post-infusion: i4.5 7.8
ml/min/1.73 m2) as compared with baseline 24 hour C. on the
sham infusion day (13.6 6.7 ml/min/1.73 m2), The same was true
for coadministration with butizid (1 to 3 hours post-infusion:
14.9 6.4 mI/min/i.73 m2; 3 to 6 hours post-infusion: 14.6 6.4
ml/minhl.73 m2) as compared with baseline 24 hour Ce,. (15.0
7.9 ml/min/1.73 m2).
Blood pressure (MAP) and heart rate did not change signifi-
cantly after the administration of torasemide. Mean MAP
changed neither during coadministration of the diuretics nor
during sham infusion (Table 4). Mean patients body weight did
not change during the study. It was 74.4 7.7 kg on placebo
infusion day before the study day when torasemide was infused
alone, 74.4 7.9 kg on torasemide infusion day, 74.4 7.6 kg on
placebo infusion day before the study day when torasemide was
infused with butizid, and 74.4 7.9 kg on the day of torasemide
and butizid coadministration.
Pharmacokinetic analyses
Figure 4 shows mean 24 hour cumulative urinary excretion of
torasemide and its main metabolites, that is, Ml (less active than
torasemide), M3 (as active as torasemide) and MS (inactive
metabolite). No significant differences in urine excretion were
found when torasemide was infused with placebo or in combina-
tion with butizid.
Discussion
The present study clearly shows that coadministration of the
thiazide diuretic, butizid, markedly increases the efficacy of the
loop diuretic torasemide in patients with advanced and even
preterminal renal failure. This finding contrasts with repeated
recommendations to withhold thiazides in such patients because
of their assumed inefficacy [1—31. Maximally effective doses of loop
diuretics increase fractional excretion of chloride and sodium to
20 to 30%. This is seen with 200 mg furosemide i.v. and 100 mg
torasemide i.v. [27]. In our patients with advanced renal failure
FE1 and FENa were further increased by more than 30% when an
effective intravenous dose of torasemide was combined with
butizid. Coadministration of both types of diuretics was shown to
increase chioruresis and natriuresis even in patients on maintain-
ance hemodialysis (unpublished data). The remarkable efficacy of
thiazides may be related, at least in part, to their long duration of
action. When loop diuretics with short half-life are administered,
antinatriuresis, that is, a decrease of sodium excretion below
baseline, is observed after a few hours. This socalled rebound
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Fig. 3. Antinatriuretic rebound response in
three patients (A, B and C) with advanced renal
failure after infusion of torasemide plus placebo
or in combination with butizid. The hourly
excretion of sodium is given as multiples of
hourly UNaV on the preceding sham day.
Symbols are: (0) infusion of torasemide plus
placebo; (•) infusion of torasemide plus
butizid.
Table 3. Cumulative 24-hour urine volume (UV) and solute excretion and 24-hour endogenous creatinine clearance (Cr)
UV Uosm UK+ U0*c UMg** Ccr
I/minI]. 73 m2ml/24 hr mOsm/24 hr mmol/24 hr m
Baseline (S + S) 2340 424b 771 157b 52 10 1.3 0.6 3.1 0.9 13.6 6.7
T + S 2956 603 898 186 61 15 2.5 1.6 3.4 1.0 13.4 6.9
Baseline (S + 5) 2343 SO8 746 l35' 51 17 1.2 O.4' 3.1 0.9 15.0 7.9
T + B 3216 73T 1011 238C 64 20 2.1 1.2c 3.7 1.0 13.0 5.7
Abbreviations are: S, sham infusion; T, torasemide infusion; B, butizid infusion.
up < "p < 0.01, sham vs. drug administration
P < 0.05, torasemide plus placebo vs. torasemide plus butizid
Table 4. Mean arterial blood pressure (MAP) and heart rate
MAP mmHga Heart rate beats/mm
8 a.m. 11 a.m. 2 p.m. 8 a.m. 11 a.m. 2 p.m.
Baseline (S + S) 101 18 104 11 110 18 71 18 67 16 66 15
T + S 101 12 105 10 107 15 72 12 67 10 68 10
Baseline (S + S) 101 15 106 12 106 13 71 15 66 12 66 14T+B 100±14 103±11 103±15 70±14 67±11 67±15
Abbreviations are: 5, sham infusion; T, torasemide infusion; B, butizid infusion.
a Patients did not take their usual (antihypertensive) medication on the study days
phenomenon tends to negate a beneficial long-term effect of loop
diuretics on sodium balance [12, 19]. Inhibition of chloride and
sodium reabsorption by butizid was demonstrable throughout the
observation period, and the difference between torasemide mono-
therapy and combination therapy with torasemide plus butizid
increased progressively with the time of observation. As discussed
below, thiazides may therefore be uniquely suited to interfere with
the rebound phenomenon. Fractional excretion of chloride (FE1)
increased more than FENa. The greater responsiveness of FEE, is
well explained by more distal exchange of sodium for other ions.
With respect to the mechanisms underlying the enhanced
potency of loop diuretics in combination with thiazides, it is
obvious that neither changes in systemic hemodynamics nor
changes in GFR are involved, since blood pressure, heart rate
and endogenous creatinine clearance remained unchanged with
diuretic administration in our patients. A further potential con-
founding variable may be a pharmacokinetic interaction between
torasemide and butizid. It is well known that the action of
diuretics, especially of loop diuretics, depends on their luminal
concentration within the renal tubule [3, 21]. Our pharmacoki-
netic evaluation documented that urinary concentrations of to-
rasemide (and the urinary concentrations of its main metabolites)
did not differ whether it was given alone or in combination with
butizid. Because no suitable assay for butizid is available, its
concentration in the urine could not be measured.
The results of our study are in line with uncontrolled clinical
observations which showed that addition of a diuretic acting on
the distal tubule tended to increase natriuresis in patients with
elevated serum creatinine who had been pretreated with ioop
diuretics [281. However, this therapeutic approach had so far
never been validated in controlled clinical studies. The mecha-
nisms by which thiazides enhance sodium and chloride excretion
in patients with advanced renal failure treated with loop diuretics
deserve comment. Thiazide diuretics are usually considered to be
low ceiling diuretics, since they act late in the nephron and
increase sodium excretion only by 5 to 10% [1—51. This is,
Fig. 4. Mean urinary excretion of torasemide (T) and its main metabolites
(Ml, M3 and M5) in patients with advanced renal failure (N 10) after
torasemide inftsion plus placebo or in combination with butizid. Symbols
are: (0) infusion of torasemide plus placebo; (•) infusion of torasemide
plus butizid; (— — —) M3; (") M1; (—) torasemide; (- -) M5.
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nounced diuresis particularly from 3 to 24 hours postdosing as
compared to torasemide alone. Third, administration of a thiazide
-
.. may interfere with the so-called "rebound effect" after ioop
-
-
diuretic treatment, that is, with antinatriuresis after the short
acting natriuretic effect of the loop diuretic has waned [17—19].
The mechanisms of the rebound phenomenon are not completely
understood. Reduction of extracellular volume may play a role,
since it is reduced by a high salt intake [18]. Post-diuretic
activation of the renin-angiotensin system or the sympathetic
system is not a prerequisite, since ACE inhibition and a-adren-
ergic receptor blockade do not obliterate the antinatriuretic
rebound [17, 35, 36]. In addition, there is evidence that volume-
_____________________
independent intrinsic renal mechanisms of sodium retention are
also involved [37, 38]. While the antinatriuretic effect has been0 3 6 12 18 24 well documented in subjects with normal renal function, it has so
T h far not been clear whether it occurs in patients with impairedime, ours renal function as well. Volume expansion, commonly present in
such patients may interfere with rebound. In the present study we
documented antinatriuresis at least in some patients in spite of a
high dietary sodium load. Coadministration of butizid clearly
prevented such antinatriuresis after torasemide.
In conclusion, thiazides markedly increase the natriuretic and
chioruretic potential of ioop diuretics even in patients with
advanced renal failure: (i) by amplifying sodium and chloride
excretion and, at least in some patients, (ii) by interfering with the
antinatriuretic rebound. Coadministration of thiazides with loop
diuretics is therefore a rational therapeutic strategy even in
patients with advanced renal failure.
however, not due to an intrinsically low diuretic potency of the
substance, but only due to the delivery of small amounts of sodium
(and chloride) to the site of action of thiazides. Since under
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